



New low back pain treatment trial to adopt dorsaVi technology

Key highlights:

- **dorsaVi's ViMove2™ technology to be used to treat chronic low back pain in new clinical trial**
- **Deal worth more than \$205K to dorsaVi**
- **Important follow-up project from Randomised Controlled Trial conducted in 2015 which found patients using ViMove technology showed increased functional activity and decreased pain compared to patients receiving standard care**
- **\$4.8 billion is spent on low back pain management every year in Australia and has been identified as a major public health problem¹**

Melbourne, Australia, 10 April 2018: dorsaVi (ASX: DVL) today announced that a new clinical trial assessing low back pain treatment will utilise ViMove2™ technology to manage patients. The project includes the use of 100 ViMove2™ devices and the value of the deal is worth more than \$205K.

The trial, which will be led by the School of Physiotherapy and Exercise Science at Curtin University, is an important follow up from a 2015 publication which demonstrated the effectiveness of dorsaVi's clinical technology. This new research, featuring 490 patients, is a significantly larger trial, and uses dorsaVi's new ViMove2™ technology, combining clinician and patient apps with the FDA cleared mini-sensors.

Curtin University was awarded a competitive grant for the trial from the National Health and Medical Research Council (NHMRC), which included purchase of dorsaVi's ViMove2 equipment. This reflects an unmet patient and public health need in seeking improved treatments for chronic low back pain. In Australia, 3.7 million people experience back pain² and \$4.8 billion is spent each year on low back pain management³.

dorsaVi CEO Dr Andrew Ronchi noted: "We are pleased to see that dorsaVi's technology continues to be recognised as a leading and objective biofeedback measure in clinical setting and applications. In particular, this trial will use our technology to help assess low back pain treatments – an increasing major public issue, given there are an estimated 540 million people globally affected by back pain at any one time⁴."

– ENDS –

¹ Monash University, Global Burden of low back pain – a consequence of medical negligence and misinformation, <https://www.monash.edu/news/articles/global-burden-of-low-back-pain-a-consequence-of-medical-negligence-and-misinformation>

² Australian Institute of Health and Welfare, Back Problems, <https://www.aihw.gov.au/reports/arthritis-other-musculoskeletal-conditions/back-problems/what-are-back-problems>

³ Monash University, Global Burden of low back pain – a consequence of medical negligence and misinformation, <https://www.monash.edu/news/articles/global-burden-of-low-back-pain-a-consequence-of-medical-negligence-and-misinformation>

⁴ Hartvigsen, JanBuchbinder, Rachele et al., What low back pain is and why we need to pay attention, <http://www.thelancet.com/journals/lancet/article/PIIS0140>

For more information about dorsaVi or to arrange an interview, please contact:

MEDIA
Megan Connell
dorsaVi
0416 116 526
mconnell@dorsavi.com

INVESTOR
Rebecca Wilson
WE Buchan
0417 382 391
rwilson@buchanwe.com.au

About dorsaVi

dorsaVi (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in elite sports, occupational health and safety and clinical applications. dorsaVi believes its wearable sensor technology enables – for the first time – many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours.

Our technology has applications across three sectors:

- **Clinical:** ViMove and ViMove2 are transforming the management of patients by providing an objective assessment, monitoring outside the clinic and immediate biofeedback. ViMove is currently used by medical and physiotherapy practices in Australia, the United Kingdom, and the United States. ViMove2 is currently used in Australia and the United Kingdom.
- **Elite Sports:** ViPerform is allowing coaches and medical teams managing elite athletes and teams to screen athletes and provide objective evidence for decisions on return to play, measure biomechanics and provide immediate biofeedback out on the field, tailor and track training programs and optimise technique and peak performance. ViPerform is being used by AFL and NRL clubs, England and Wales Cricket Board and Board of Control for Cricket in India, Barclays Premier League (EPL) clubs in the UK and US-based sports clubs from the National Basketball Association (NBA), the Major Soccer League (MLS) and the National Football League (NFL) as well as various Olympic teams and athletes internationally.
- **OHS:** We combine innovation, measurement, and quality to reduce workplace incidents, costs, meet compliance and improve brand reputation. ViSafe and myViSafe enable employers to assess the risk of injury for employees as well as test the effectiveness of proposed changes to workplace design, equipment or methods based on objective evidence. Our workplace safety solutions are used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor), Crown and BHP Billiton.

Further information is available at www.dorsavi.com.